Task: Table-QA (source dataset: FinQA)

Task: 
You are given a table containing structured data and a natural language question referring to the table. Your goal is to analyze the table and provide an accurate and concise answer based on the given data.

Instructions:
1. Understand the Table: Examine the structure, headers, and data in the table. Identify relevant columns and rows related to the question.
2. Interpret the Question: Determine whether the question requires direct retrieval, aggregation, comparison, sorting, filtering, or inference.
3. Extract the Answer: Use logical reasoning and numerical operations (if necessary) to derive the correct response from the table.
4. Format the Answer: No explanation, return the answer in a structured JSON format: {"answer": <answer>}. If the question cannot be answered due to missing or ambiguous data, return a JSON response with {"answer": null}.

Table:
| ( millions )     | 2007         | 2006       | 2005       |
|:-----------------|:-------------|:-----------|:-----------|
| interest expense | $ 210        | $ 122      | $ 82       |
| interest income  | -132 ( 132 ) | -51 ( 51 ) | -56 ( 56 ) |
| total            | $ 78         | $ 71       | $ 26       |

Question:
in 2006 what was the percent of the recognized a pre-tax gain to the proceeds of the sale of its global branded pharmaceuticals businesses


pre_text: research , development and related expenses : research , development and related expenses ( r&d ) as a percent of net sales decreased 1.0 percentage point in 2007 when compared to 2006 , as expenses incurred in 2006 in the company 2019s now-divested r&d-intensive pharmaceuticals business did not repeat in 2007 .
non-pharmaceutical ongoing r&d expenses , after adjusting for the following items , were up approximately 11% ( 11 % ) in dollars , as the company continued to aggressively invest in future technologies and growth opportunities .
2006 spending included a $ 95 million in-process research and development charge ( discussed in note 2 ) and $ 75 million in restructuring actions ( note 4 ) , which increased 2006 r&d as a percent of sales by 0.7 percentage points .
in dollars , r&d spending decreased $ 154 million when comparing 2007 to 2006 , with the change in restructuring and other items year-on-year decreasing r&d by $ 174 million , 2006 pharmaceutical sg&a spending decreasing $ 120 million and other r&d spending increasing $ 140 million , or approximately 11% ( 11 % ) in dollars , reflecting 3m 2019s continuing commitment to fund future growth for the company .
r&d increased as a percent of sales by 0.6 of a percentage point , or $ 248 million , when comparing 2006 to 2005 .
the 2006 spending included a $ 95 million in-process research and development charge ( discussed in note 2 ) and $ 75 million in restructuring actions ( note 4 ) .
other spending increased approximately $ 78 million , representing an increase of approximately 6% ( 6 % ) compared with 2005 .
gain on sale of businesses : in january 2007 , 3m completed the sale of its global branded pharmaceuticals business in europe to meda ab .
3m received proceeds of $ 817 million for this transaction and recognized , net of assets sold , a pre-tax gain of $ 781 million in 2007 ( recorded in the health care segment ) .
in june 2007 , 3m completed the sale of its opticom priority control systems and canoga traffic detection businesses to torquest partners inc. , a toronto-based investment firm .
3m received proceeds of $ 80 million for this transaction and recognized , net of assets sold , transaction and other costs , a pre-tax gain of $ 68 million ( recorded in the display and graphics segment ) in 2007 .
in december 2006 , 3m completed the sale of its global branded pharmaceuticals businesses in the united states , canada , and latin america region and the asia pacific region , including australia and south africa .
3m received proceeds of $ 1.209 billion for these transactions and recognized a pre-tax gain on sale of $ 1.074 billion in 2006 ( recorded in the health care segment ) .
for more detail , refer to note 2 .
operating income : 3m uses operating income as one of its primary business segment performance measurement tools .
operating income margins over the past several years have been in excess of 22% ( 22 % ) , helped by solid sales growth and an ongoing strong commitment to maintaining operational discipline throughout 3m 2019s global operations .
operating income margins of 25.3% ( 25.3 % ) in 2007 were positively impacted by 2.8 percentage points ( $ 681 million ) from the gain on sale of businesses and real estate , net of environmental liabilities , restructuring and other exit activities .
operating income margins of 24.8% ( 24.8 % ) for 2006 were positively impacted by 2.2 percentage points ( $ 523 million ) from the gain on sale of portions of the pharmaceuticals business , net of restructuring and other actions .
adjusting for the preceding items , operating income margins in 2007 were similar to 2006 .
interest expense and income: .
post_text: interest expense : interest expense increased year-on-year in both 2007 and 2006 , primarily due to higher average debt balances and higher interest rates .
interest income : interest income increased in 2007 due to higher average cash , cash equivalent and marketable securities balances and higher interest rates .
interest income was lower in 2006 , with lower average cash , cash equivalent and marketable securities balances partially offset by higher interest rates. .
label: 0.88834
qa: answer: 88.8%
explanation: the percent of the recognized a pre-tax gain to the proceeds of the sale of its global branded pharmaceuticals businesses was 88.8%
ann_text_rows: 2
steps: op: divide1-1
arg1: 1.074
arg2: 1.209
res: 88%
program: divide(1.074, 1.209)
gold_inds: text_2: 2006 spending included a $ 95 million in-process research and development charge ( discussed in note 2 ) and $ 75 million in restructuring actions ( note 4 ) , which increased 2006 r&d as a percent of sales by 0.7 percentage points .
text_12: 3m received proceeds of $ 1.209 billion for these transactions and recognized a pre-tax gain on sale of $ 1.074 billion in 2006 ( recorded in the health care segment ) .
exe_ans: 0.88834
tfidftopn: text_7: gain on sale of businesses : in january 2007 , 3m completed the sale of its global branded pharmaceuticals business in europe to meda ab .
program_re: divide(1.074, 1.209)
model_input: text_8
3m received proceeds of $ 817 million for this transaction and recognized , net of assets sold , a pre-tax gain of $ 781 million in 2007 ( recorded in the health care segment ) .
text_10
3m received proceeds of $ 80 million for this transaction and recognized , net of assets sold , transaction and other costs , a pre-tax gain of $ 68 million ( recorded in the display and graphics segment ) in 2007 .
text_12
3m received proceeds of $ 1.209 billion for these transactions and recognized a pre-tax gain on sale of $ 1.074 billion in 2006 ( recorded in the health care segment ) .